Skip to main content

Investors piled into a Bayer bond on Wednesday that will help pay for a long-negotiated settlement of lawsuits claiming its widely used weedkiller Roundup caused cancer.

Demand for the four-tranche bond sale, whose proceeds will include the litigation payments, exceeded €17.5-billion (US$19.7-billion), nearly three times the €6-billion Bayer will raise, according to a lead manager update seen by Reuters.

After more than a year of talks, Bayer agreed to pay as much as US$10.9-billion last week to settle nearly 100,000 U.S. lawsuits to end legal disputes it inherited with its US$63-billion takeover of Monsanto in 2018.

“Strong appetite [for the bond] seems driven by the fact that uncertainty surrounding the Roundup litigation has now been removed,” said ABN AMRO strategist Shanawaz Bhimji.

The settlement has propped up Bayer’s credit outlook with Fitch Ratings and Moody’s revising their negative outlooks from three-notches above junk territory to stable on Monday.

Bayer will raise the total amount through four-year, 6.5, 9.5 and 12-year bonds, each set to raise €1.5-billion when the deal prices later on Wednesday, according to the lead manager.

Your time is valuable. Have the Top Business Headlines newsletter conveniently delivered to your inbox in the morning or evening. Sign up today